The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer

Adjuvant therapy for resected pancreatic cancer remains one of the most highly debated topics in oncology. For patients with resectable disease that have undergone upfront resection, without neoadjuvant therapy, there exists numerous treatment options (1). These include chemotherapy (CT) alone, CT followed by chemoradiotherapy (CRT), and CRT between separate courses of CT. This lack of consensus largely stems from the conflicting results of seminal prospective trials (2-5), as well as the lack of a completed phase III trial to date regarding the direct utility of radiotherapy (RT) in the adjuvant setting